Cargando…

Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis

BACKGROUND: Most of the randomized clinical trials that led to the wide use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation (AF) originated from western countries. AIM: To systematically review and quantitatively synthesize the real-world da...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Wei-Jia, Archontakis-Barakakis, Paraschos, Palaiodimos, Leonidas, Kalaitzoglou, Dimitrios, Tzelves, Lazaros, Manolopoulos, Apostolos, Wang, Yu-Chiang, Giannopoulos, Stefanos, Faillace, Robert, Kokkinidis, Damianos G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Meta-Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069517/ https://www.ncbi.nlm.nih.gov/pubmed/33968307 http://dx.doi.org/10.4330/wjc.v13.i4.82

Ejemplares similares

Comparative effectiveness of dabigatran, rivaroxaban, apixaban and warfarin in the management of patients with non-valvular atrial fibrillation
por: Pink, Joshua, et al.
Publicado: (2013)

Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study
por: Kjerpeseth, Lars J., et al.
Publicado: (2019)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
por: Martinez, Brandon K., et al.
Publicado: (2018)

Frailty in patients undergoing transcatheter aortic valve replacement: from risk scores to frailty-based management
por: Tzoumas, Andreas, et al.
Publicado: (2021)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
por: Norby, Faye L., et al.
Publicado: (2017)

Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the United States
por: Lip, Gregory Y. H., et al.
Publicado: (2016)

Combination of low-dose glucocorticosteroids and mineralocorticoids as adjunct therapy for adult patients with septic shock: A systematic review and meta-analysis of randomized trials and observational studies
por: Archontakis Barakakis, Paraschos, et al.
Publicado: (2019)

Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
por: Tepper, Ping G., et al.
Publicado: (2018)

Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups
por: Gómez-Outes, Antonio, et al.
Publicado: (2013)

Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban
por: Lip, Gregory Y. H., et al.
Publicado: (2018)

Ethnic and sex-based differences in outcomes after out-of-hospital cardiac arrest: a glimpse of the largest municipal healthcare system in the United States
por: Nagraj, Sanjana, et al.
Publicado: (2023)

Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients
por: Úlehlová, Jana, et al.
Publicado: (2021)

Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States
por: Coleman, Craig I., et al.
Publicado: (2016)

Safety of apixaban and rivaroxaban compared to warfarin after cardiac surgery
por: Naik, Kushal D., et al.
Publicado: (2022)

Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography
por: Artang, Ramin, et al.
Publicado: (2021)

Resolution of a warfarin and dabigatran-resistant left atrial appendage thrombus with apixaban
por: Miwa, Yosuke, et al.
Publicado: (2016)

Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban
por: Charlton, Blake, et al.
Publicado: (2018)

Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban
por: Ru San, Tan, et al.
Publicado: (2012)

Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system
por: Villines, Todd C, et al.
Publicado: (2019)

Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation
por: Brown, Joshua D., et al.
Publicado: (2016)

Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study
por: Rutherford, Ole-Christian W, et al.
Publicado: (2020)

Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban
por: ABDULLAH, Ahmad Salihin, et al.
Publicado: (2022)

Effects of Apixaban, Rivaroxaban, Dabigatran and Enoxaparin on Histopathology and Laboratory Parameters in Achilles Tendon Injury: An in vivo Study
por: Avci, Sema, et al.
Publicado: (2021)

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study
por: Abraham, Neena S, et al.
Publicado: (2015)

DOACs in Valvular Heart Disease: Latest Key Updates on PROACT Xa (Apixaban) and INVICTUS (Rivaroxaban)
por: Ryu, Rachel
Publicado: (2022)

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
por: Breithardt, Günter, et al.
Publicado: (2016)

Quantification of Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Serum by UHPLC-MS/MS—Method Development, Validation, and Application
por: Lindahl, Sofia, et al.
Publicado: (2018)

Analytical verification and comparison of chromogenic assays for dabigatran, rivaroxaban and apixaban determination on BCSXP and STA Compact Max analysers
por: Ćelap, Ivana, et al.
Publicado: (2020)

Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban
por: Slavik, L., et al.
Publicado: (2019)

Apixaban or Rivaroxaban Versus Warfarin for Treatment of Submassive Pulmonary Embolism After Catheter-Directed Thrombolysis
por: Groetzinger, Lara M., et al.
Publicado: (2018)

Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China
por: Wei, Hongtao, et al.
Publicado: (2021)

Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study
por: Sindet-Pedersen, Caroline, et al.
Publicado: (2017)

Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban
por: Winkle, Roger A., et al.
Publicado: (2014)

Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay
por: Artang, Ramin, et al.
Publicado: (2017)

Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study
por: Grymonprez, Maxim, et al.
Publicado: (2023)

Effectiveness and safety of rivaroxaban vs. warfarin in patients with non‐valvular atrial fibrillation and heart failure
por: Martinez, Brandon K., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4lg1385rpemosqtq19l5umqfev